Biosimilars and Value-Based Oncology Treatment Pathways

Biosimilars and Value-Based Oncology Treatment Pathways

On-Demand Webcast

This webcast is based on live proceedings from a symposium conducted at the 2nd Annual Clinical Pathways Congress.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Faculty

Robert M. Rifkin, MD, FACP
Clinical Associate Professor of Medicine
University of Colorado
Associate Chair, Hematology Research & Medical Director ñ Biosimilars
McKesson Specialty Health/US Oncology Network
Woodlands, Texas

Gary H. Lyman, MD, MPH
Professor of Medicine
University of Washington
Co-Director, Hutchinson Institute for Cancer Outcomes Research (HICOR)
Fred Hutchinson Cancer Research Center
Seattle, Washington

Intended Learners

This activity is designed for directors of oncology practice programs and cancer centers, oncologists, hematologists, commercial and government payers, pathway development executives, reimbursement specialists, specialty pharmacists, HEOR specialists, and other healthcare professionals interested in learning how to implement, integrate, and measure treatment pathways.

Learning Objectives
 
After completing this activity, participants should be able to:
  • Review the key clinical and regulatory concepts for the approval of biosimilar oncology treatments including totality of evidence (safety, efficacy, immunogenicity data, etc), complex data analytics, indication extrapolation, and interchangeability/substitution requirements
  • Evaluate the latest advances, available clinical data, and emerging research surrounding biosimilar oncology treatments and their impact on the standard of oncology care
  • Highlight the clinical, cost, and regulatory considerations that impact the integration of oncology biosimilar treatments into clinical pathways 
  • Discuss the anticipated benefits and challenges of integrating emerging biosimilars into oncology treatment pathways
Activity Overview

This on-demand webcast is a simulcast from the live Clinical Pathways Congress symposium on September 8, 2017.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: November 30, 2017
Expiration Date: November 30, 2018

Estimated time to complete: 1 hour

For questions regarding this educational activity, please call 609-371-1137.

There is no fee associated with this activity.

ACPE Credit Policy 
Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Accreditation

  In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this live activity for a maximum of 1 AMA PRA Category 1 Credits.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 1 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour.

CPE

This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 0276-0000-17-024-H01-P).

This educational activitiy is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may
contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520.
The Senior Manager, Accreditation and Compliance, will review the grievance and respond within 30 days of receiving the written statement. If the
participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second
level of review.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. The faculty has reported the following:

Dr. Lyman: PI on Research Grant to Fred Hutchinson: Amgen
Dr. Rifkin: Advisory Board:  Amgen, Coherus, EMD Serono, Pfizer

Dr. Stevenson have disclosed no relevant financial relationships with any commercial interests.

Jennifer Browne, Mary Johnson, Mike Kearney, Michelle Montgomery, Randy Robbin, John Savage, and Leslie Sharp from NACCME have disclosed no relevant financial relationships with any commercial interests.

Independent Clinical Reviewer:  James Stevenson, MD, Vice-Chairman, Department of Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Faculty members have disclosed that off-label/unapproved uses of drugs and/or devices will be discussed: Biosimilars in Pipeline, Approved, Not Released.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individualís consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgement must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity has been supported through an independent educational grant from Teva Pharmaceuticals.